Audit: QRS - Riboflavin for Health & Longevity

Audit conducted on 22/09/2026 19:44 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	84
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells trace to ER lines 358/360/364; time-to-effect cells to ER line 414; benefit and risk items to the ER Expected Benefits and Potential Risks & Side Effects headings; monitoring rows to the ER biomarker table (lines 448–454); cadence to ER line 444.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s hedge on the genotype finding (“is genuinely open”, ER line 490) is carried verbatim into [at_a_glance].
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication wording preserves “unsupervised” and the ≥100 mg threshold from ER line 330; no claim is up- or down-graded.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	[stop_items] come only from the ER’s “Populations who should avoid Riboflavin” block; [caution_items] only from the ER’s Key Interactions bullets; no Benefit-/Risk-Modifying Factor content is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register matching the ER; [at_a_glance] is near-verbatim from the ER Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Thresholds, doses and durations are given concretely; framing is neutral and actionable.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring content is stated descriptively (“Split doses are taken with breakfast and lunch”), not issued as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives or second-person instructions anywhere in the document voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of “should”, “must”, “recommend” or “advise” in the document voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No occurrence of “you” / “your” in the document voice.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms appear only where the ER itself requires them (biomarker names, genotype labels); the lede stays in plain language.
2.8	Information is presented in a concise and very compact manner	🟢	Gate, benefit and risk items are short fragments; monitoring cells are trimmed versions of the ER table entries.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no second-person address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to genotype, to run a 16-week low-dose trial and to keep a migraine diary.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily home blood-pressure logging for eight weeks and specialty-laboratory activation-coefficient testing are presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring panel assumes access to a specialty functional assay and MTHFR genotyping.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede separates the one well-supported high-dose use from the genotype-restricted, still-open blood-pressure claim.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging”; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No “pill”, “shot” or “by mouth”; lede phrasing (“sold as a supplement”, “Excess is excreted”, “vivid yellow urine”) is taken from the ER Conclusion.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte (lines 446, 489, 535, 566, 578, 606, 628, 632–634, 747).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 distinct template variables present; the repeated marker_#* and qualitative_item# groups are expanded to 7 and 4 instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against the template shows differences only inside data-qrs-var spans and the metadata block; website="evidence_review", website="audit" and website="full_review" spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “High-dose migraine protocol”, “Targeted low dose for the TT genotype” and “Best time of day” are verbatim from ER lines 360, 358 and 364; monitoring row labels are verbatim from the ER table column 1.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No abbreviation or paraphrase of any label.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji anywhere in the file; the ER’s “⚠️ Conflicted” marker is correctly not carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is reduced to fragments; the item counts that drive the length (13 interactions, 7 biomarkers) are mandated by 9.2 and 14.2, and no section is padded with prose or extended past the template structure.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” on line 3, closing “—” on line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Entirely inside an HTML comment; no duplicate surface in the header or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: riboflavin_2026-0815-0221_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.22, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0922-1912.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: riboflavin_2026-0815-0221_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Riboflavin for Health & Longevity - Quick Reference Sheet”; ER canonical_topic is “Riboflavin for Health & Longevity”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Riboflavin for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/22/2026”, matching qrs_creation_date 2026-0922.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template’s fixed subline; no alternate-names line despite the ER carrying six.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Riboflavin, or vitamin B2, is a water-soluble vitamin found in dairy and organ meats and sold as a supplement.”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three paragraphs of the ER Conclusion (lines 488–492) into five sentences.
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence of the ER Conclusion.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “MTHFR 677TT” is correctly rendered as “A gene variant”.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect sizes; the ER’s “59% versus 15%” and “5.6 mmHg” figures are excluded.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Both items come from the “Populations who should avoid Riboflavin” block at ER lines 328 and 330.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Both of the ER’s two avoid-populations are present, and only those.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 569 and 570–573.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s mechanistic tail “since clearance of the surplus depends on renal excretion” is stripped; no trailing dash clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The eGFR <30 mL/min/1.73 m² threshold, CKD stages 4–5, dialysis, the ≥100 mg/day dose threshold and “at any dose” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER does name two such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All thirteen items map one-to-one onto the ER bullets at lines 300–324.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 13 ER interaction bullets are represented; neither avoid-population is duplicated here.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Thirteen <li> elements at lines 581–596.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER Severity/Consequence/Mitigation tail is stripped; the ER’s “Other interventions — “ prefix is correctly dropped in favour of the substance after the dash.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved for phenothiazines/TCAs, anticholinergics, barbiturates and tetracyclines; the MTHFR 677TT qualifier is kept on the antihypertensive item and “(additive)” on the three nutrient items.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER lists thirteen interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets at lines 358, 360 and 364.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two indication-defining dose regimens (400 mg migraine, 1.6 mg TT genotype) plus timing/administration — the three most decision-relevant of the twelve ER protocol bullets.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies twelve protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Migraine, riboflavin status and blood pressure/homocysteine — exactly the three the ER names at line 414.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Migraine and riboflavin status are the ER’s two High-tier benefits; blood pressure/homocysteine is Medium tier and sits last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated from ER line 414.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine ER benefit headings (lines 166–220) are represented across the four tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four present at lines 537, 543, 549 and 555, each in the correct tier.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a semicolon-separated list of ER benefit headings; no magnitudes or citations carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All five ER risk headings (lines 248–276) are represented across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four present at lines 608, 611, 614 and 617, each in the correct tier.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	“Bright yellow urine”, “Diarrhea and increased urination”, “Delayed hypersensitivity reactions” — headings only, no magnitudes.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All seven rows derive from the ER Monitoring Protocol & Defining Success biomarker table (lines 448–454).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER biomarkers present: activation coefficient, plasma riboflavin, homocysteine, MTHFR C677T, hemoglobin with MCV, ferritin, home blood pressure.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 737 condenses ER line 444: 12–16 weeks then annually, home BP twice daily for eight weeks, migraine diary at three months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All four items derive from the ER’s “Qualitative markers worth tracking” bullets (lines 458–464).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All four ER qualitative markers present: migraine diary, deficiency signs, energy and exercise tolerance, urine color as adherence check.

Issues 22/09/2026 19:44

Pass rate 100.00%. No issues found.

Issues 22/09/2026 19:38

1. 1.1 — Garbled qualitative marker wording: qualitative_item_3 (line 759) says “Daytime energy and exercise tolerance, particularly from a deficient activation coefficient”, dropping the ER’s “in anyone starting from” (ER line 462) and turning a population qualifier into an unsupported causal claim.
2. 4.3 — Drug-class labels abbreviated: Two caution_items shorten the ER’s class labels — “tricyclics” at line 581 for the ER’s “tricyclic antidepressants” (ER line 300), and “Tetracyclines” at line 587 for the ER’s “Tetracycline antibiotics” (ER line 312).

Fixes 22/09/2026 19:38

1. 1.1 — Qualitative marker wording restored: qualitative_item_3 changed from “particularly from a deficient activation coefficient” to “particularly starting from a deficient activation coefficient”, restoring the ER’s population qualifier instead of implying a causal link.
2. 4.3 — Drug-class labels unabbreviated: caution_items now read “Phenothiazines and tricyclic antidepressants (chlorpromazine, imipramine, amitriptyline)” and “Tetracycline antibiotics (doxycycline, minocycline)”, matching the ER’s class labels.

Issues 22/09/2026 19:32

1. 9.5 — Antihypertensive genotype qualifier dropped: The Key Interactions item at line 589 reads only “Antihypertensive drugs of any class”, losing the ER’s restriction of the additive blood-pressure lowering to “the MTHFR 677TT genotype” (ER line 316), and lacking the “(additive)” marker its three sibling additive items carry.

Fixes 22/09/2026 19:32

1. 9.5 — Antihypertensive genotype qualifier restored: Changed the Key Interactions item from “Antihypertensive drugs of any class” to “Antihypertensive drugs of any class (additive in the MTHFR 677TT genotype)”, restoring the ER’s applicability qualifier and matching the “(additive)” marker used by the sibling additive items.

Issues 22/09/2026 19:21

1. 4.5 — Sheet overflows one A4 page: Estimated rendered height is roughly 1.8 A4 pages. The main contributors are the Monitoring “Why” cells (lines 650-737), which carry near-verbatim ER sentences of up to 100 characters, the ~250-character cadence line (lines 743-747), the Qualitative Assessment items of up to 133 characters (lines 755-777), and several two-line Key Interactions entries (lines 582-596).

Fixes 22/09/2026 19:21

1. 4.5 — Monitoring “Why” cells condensed: Shortened all seven marker_#_why cells to single-line phrases, e.g. “Riboflavin is required to mobilize stored iron, so iron-refractory anemia warrants a riboflavin check” to “Stored-iron mobilization depends on riboflavin”.
2. 4.5 — Monitoring targets trimmed: Tightened marker_2_target, marker_4_target and marker_5_target (e.g. “No range applies — a one-time categorical result of CC, CT or TT” to “No range applies — one-time result of CC, CT or TT”) while keeping every threshold and category.
3. 4.5 — Monitoring cadence shortened: Reduced monitoring_cadence from ~250 to ~190 characters, retaining all three cadences (12–16 weeks then annually, twice-daily home blood pressure for eight weeks, migraine diary at three months).
4. 4.5 — Qualitative items reduced to one line: Trimmed qualitative_item_1, qualitative_item_2 and qualitative_item_3 to single rendered lines without dropping any tracked sign.
5. 4.5 — Key Interactions entries de-wrapped: Shortened three two-line entries to one line (“Phenothiazines and tricyclic antidepressants” to “Phenothiazines and tricyclics”, “Anticholinergic drugs” to “Anticholinergics”, “Tetracycline antibiotics” to “Tetracyclines”), keeping every named example drug.
6. 4.5 — Benefits and Protocol overflow trimmed: Cut benefits_low to a single rendered line and reduced action_2_sub from three lines to two (“the exact dose used in every positive homocysteine and blood-pressure trial” to “the dose used in every positive trial for this genotype”).

Issues 22/09/2026 19:19

1. 12.3 — Qualifier kept in benefits item: [benefits_medium] (line 546) carries the parenthetical qualifier “(conflicted)” and redundantly repeats “in the MTHFR 677TT genotype” for both benefits, where the Medium tier already encodes evidence strength.

Fixes 22/09/2026 19:19

1. 12.3 — Qualifier stripped from benefits item: [benefits_medium] changed from “Blood pressure lowering in the MTHFR 677TT genotype (conflicted); homocysteine lowering in the MTHFR 677TT genotype” to “Blood pressure and homocysteine lowering in the MTHFR 677TT genotype”, removing the “(conflicted)” qualifier and the duplicated genotype phrase.